TABLE 1.
Plasmids utilized for present studies
| Plasmid or mutant | Expressed protein or substitutiona | Restriction site | Reference or source |
|---|---|---|---|
| pCAGGS.MCS | Ampicillin selec. marker | Multiple | 19 |
| pF42 | EBV gp42 | EcoRI/BgIII | 12 |
| pF25 | EBV gL | EcoRI/BgIII | 12 |
| pF85 | EBV gH | ClaI/BgIII | 12 |
| pF110 | EBV gB | EcoRI/ClaI | 12 |
| pEGFP-N1 | EGFP | Multiple | Clontech |
| pOS2 | T7 RNA polymerase, G418 selec. marker | 39 | |
| pT7EMCLuc | T7 luciferase | 31 | |
| LI12 | EBV gp42 LFKQL-F | PmeI | This study |
| LI27 | CLNNF-L | PmeI | This study |
| LI82 | CLNNW-T | PmeI | This study |
| LI93 | MFKHQ-N | PmeI | This study |
| LI104 | CLNSN-T | PmeI | This study |
| LI112 | CLNTY-K | PmeI | This study |
| LI118 | CLNIY-F | PmeI | This study |
| LI122 | MFKQK-K | PmeI | This study |
| LI134 | CLNSA-E | PmeI | This study |
| LI148 | MFKHD-I | PmeI | This study |
| LI149 | CLNNI-L | PmeI | This study |
| LI179 | CLNID-G | PmeI | This study |
| LI193 | CLNNC-T | PmeI | This study |
| LI195 | CLNTY-V | PmeI | This study |
| LI206 | CLNTH-H | PmeI | This study |
| LI210 | LFKHS-F | PmeI | This study |
| LI216 | CLNSF-C | PmeI | This study |
| W44A | Trp to Ala | Acc65I | This study |
| Q89A | Gln to Ala | Acc65I | This study |
| T104A | Thr to Ala | XhoI | This study |
| Y107A | Tyr to Ala | BsaJI | This study |
| W125G | Trp to Gly | BsrDI | This study |
| R154A | Arg to Ala | MunI | This study |
| E160A | Glu to Ala | Esp3I | This study |
| Y185F | Tyr to Phe | BglII | This study |
| F210A | Phe to Ala | AflII | This study |
| R220A | Arg to Ala | HindIII | This study |
a
The mutant EBV gp42-expressed protein reveals either the 5-amino-acid insert followed by the residue (after the hyphen) indicating the location (LI12 contains LFKQL inserted before residue 12F) or the change in point mutation (W44A is tryptophan to alanine).